Journal Article

Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial

Cunningham, Steven, Seddon, Paul, Babalis, Daphne, Gupta, Atul, Murray, Clare, Roberts, Graham, Kennington, Erika, Saglani, Sejal, Cornelius, Victoria, Streatfield, Claire, Carroll, William D, Fleming, Louise, Gaillard, Erol, Janani, Leila, Sinha, Ian, Nagakumar, Prasad, Weir, Elise

2024

Overview

IntroductionA minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005. While omalizumab is an effective treatment, non-response is common. A second biologic, mepolizumab which blocks interleukin 5 and targets eosinophilic inflammation, was licensed in 2018, but the licence was granted by extrapolation of adult clinical trial data to children. This non-inferiority (NI) trial will determine whether mepolizumab is as efficacious as omalizumab in reducing asthma attacks in children with severe therapy resistant asthma (STRA) and refractory difficult asthma (DA).Methods and analysisThis is an ongoing multicentre 1:1 randomised NI open-label trial of mepolizumab and omalizumab. Up to 150 children and young people (CYP) aged 6–17 years with severe asthma will be recruited from specialist paediatric severe asthma centres in the UK. Prior to randomisation, children will be monitored for medication adherence for up to 16 weeks to determine STRA and refractory DA diagnoses. Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using clinician-elicited prior distributions will be used to calculate the posterior probability that mepolizumab is not inferior to omalizumab. Secondary outcomes include Composite Asthma Severity Index, Paediatric Asthma Quality of Life Questionnaire, lung function measures (forced expiratory volume in one second (FEV1), bronchodilator reversibility), fractional exhaled nitric oxide, Asthma Control Test (ACT), health outcomes EuroQol 5 Dimension (EQ-5D) and optimal serum IgE and blood eosinophil levels that may predict a response to therapy. These outcomes will be analysed in a frequentist framework using longitudinal models.Ethics and disseminationThe study has been approved by the South Central—Berkshire Research Ethics Committee REC Number 19/SC/0634 and had Clinical Trials Authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) (EudraCT 2019-004085-17). All parents/legal guardians will give informed consent for their child to participate in the trial, and CYP will give assent to participate. The results will be published in peer-reviewed journals, presented at international conferences and disseminated via our patient and public involvement partners.Trial registration numberISRCTN12109108; EudraCT Number: 2019-004085-17.

• Publisher: British Medical Journal Publishing Group,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Adolescent / Anti-Asthmatic Agents - therapeutic use / Antibodies, Monoclonal, Humanized - therapeutic use / Asthma / Asthma - drug therapy / Biomarkers / Child / Clinical trials / Consent / Equivalence Trials as Topic / Families & family life / Female / Humans / Immunoglobulins / Male / Monoclonal antibodies / Multicenter Studies as Topic / Omalizumab - therapeutic use / Paediatric thoracic medicine / Paediatrics / Pediatrics / Protocol / Quality of Life / Randomized Controlled Trial / Randomized Controlled Trials as Topic / Respiratory Function Test / Severity of Illness Index / Steroids / Treatment Outcome